A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern

I. Jung Lee, Yu Hua Lan, Ping Yi Wu, Yan Wei Wu, Yu Hung Chen, Sheng Che Tseng, Tzu Jiun Kuo, Cheng Pu Sun, Jia Tsrong Jan, Hsiu Hua Ma, Chun Che Liao, Jian Jong Liang, Hui Ying Ko, Chih Shin Chang, Wen Chun Liu, Yi An Ko, Yen Hui Chen, Zong Lin Sie, Szu I. Tsung, Yi Ling LinI. Hsuan Wang, Mi Hua Tao

研究成果: Article同行評審

5 引文 斯高帕斯(Scopus)

摘要

Numerous vaccines have been developed to address the current COVID-19 pandemic, but safety, cross-neutralizing efficacy, and long-term protectivity of currently approved vaccines are still important issues. In this study, we developed a subunit vaccine, ASD254, by using a nanoparticle vaccine platform to encapsulate the SARS-CoV-2 spike receptor-binding domain (RBD) protein. As compared with the aluminum-adjuvant RBD vaccine, ASD254 induced higher titers of RBD-specific antibodies and generated 10- to 30-fold more neutralizing antibodies. Mice vaccinated with ASD254 showed protective immune responses against SARS-CoV-2 challenge, with undetectable infectious viral loads and reduced typical lesions in lung. Besides, neutralizing antibodies in vaccinated mice lasted for at least one year and were effective against various SARS-CoV-2 variants of concern, including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.617.2 (Delta), and B.1.1.529 (Omicron). Furthermore, particle size, polydispersity index, and zeta-potential of ASD254 remained stable after 8-month storage at 4°C. Thus, ASD254 is a promising nanoparticle vaccine with good immunogenicity and stability to be developed as an effective vaccine option in controlling upcoming waves of COVID-19.

原文English
文章編號2149353
期刊Emerging Microbes and Infections
12
發行號1
DOIs
出版狀態Published - 2023

All Science Journal Classification (ASJC) codes

  • 流行病學
  • 寄生物學
  • 微生物學
  • 免疫學
  • 藥物發現
  • 傳染性疾病
  • 病毒學

指紋

深入研究「A receptor-binding domain-based nanoparticle vaccine elicits durable neutralizing antibody responses against SARS-CoV-2 and variants of concern」主題。共同形成了獨特的指紋。

引用此